Jump to content

Ribosomopathy

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Dcirovic (talk | contribs) at 02:42, 28 May 2016 (clean up using AWB). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Ribosomopathies are diseases caused by alterations in the structure or function of ribosomal component proteins or rRNA genes, or other genes whose products are involved in ribosome biogenesis.[1][2][3]

Ribosomes

Ribosomal rRNA subunits
Ribosomal rRNA subunits

Ribosomes are essential for protein synthesis in all living organisms. Prokaryotic and eukaryotic ribosomes both contain a scaffold of ribosomal RNA (rRNA) on which are arrayed an extensive variety of ribosomal proteins (RP).[4] Ribosomopathies can arise from abnormalities of either rRNA or the various RPs.

The nomenclature of rRNA subunits is derived from each component's Svedberg unit, which is an ultracentrifuge sedimentation coefficient, that is affected by mass and also shape. These S units of the rRNA subunits cannot simply be added because they represent measures of sedimentation rate rather than of mass. Eukaryotic ribosomes are somewhat larger and more complex than prokaryotic ribosomes. The overall 80S eukaryotic rRNA structure is composed of a large 60S subunit (LSU) and a small 40S subunit (SSU).[5]

In humans, a single transcription unit separated by 2 internally transcribed spacers encodes a precursor, 45S. The precursor 45S rDNA is organized into 5 clusters (each has 30-40 repeats) on chromosomes 13, 14, 15, 21, and 22. These are transcribed in the nucleolus by RNA polymerase I. 45S is processed in the nucleus via 32S rRNA to 28S[6] and 5.8S,[7] and via 30S to 18S,[8] as shown in the diagram. 18S is a component of the ribosomal 40S subunit. 28S, 5.8S and 5S,[9] which is transcribed independently, are components of 60S. The 5S DNA occurs in tandem arrays (~200-300 true 5S genes and many dispersed pseudogenes); the largest is on chromosome 1q41-42. 5S rRNA is transcribed by RNA polymerase III.[5] It is not fully clear why rRNA is processed in this way rather than being directly transcribed as mature rRNA, but the sequential steps may have a role in the proper folding of rRNA or in subsequent RP assembly.

The products of this processing within the cell nucleus are the four principal types of cytoplasmic rRNA: 28S, 5.8S, 18S, and 5S subunits.[10]: 291  and (cite)(cite) (Mammalian cells also have 2 types of mitochondrial rRNA molecules, 12S and 16S.) In humans, as in most eukaryotes, the 18S rRNA is a component of 40S ribosomal subunit, and the 60S large subunit contains three rRNA species (the 5S, 5.8S and 28S in mammals, 25S in plants). 60S rRNA acts as a ribozyme, catalyzing peptide bond formation, while 40S monitors the complementarity between tRNA anticodon and mRNA.

Diseases

Abnormal ribosome biogenesis is linked to several human genetic diseases.

Ribosomopathy underpins most Diamond–Blackfan anemia (DBA),[2] the X-linked subtype of dyskeratosis congenita (DKCX),[11][12] Treacher Collins syndrome (TCS),[2][13] Shwachman–Diamond syndrome (SDS)[14] and 5q- myelodysplastic syndrome.(5q- MDS),(cite)(cite) North American Indian childhood cirrhosis (NAIC),[15] isolated congenital asplenia (ICAS),[15][16][17][18] and Bowen–Conradi syndrome (BWCNS), CHARGE syndrome[19][20][21][22] and ANE syndrome (ANES).[23]

The associated chromosome, OMIM genotype, phenotype phenotype, and possible disruption points are shown:

Ribosomopathies
name chromosome genotype[24] phenotype protein disruption(cite)(cite)
DBA1[24] 19q13.2 Template:OMIM2 Template:OMIM2 RPS19 30S to 18S[10]: 291 (cite)
DBA2 8p23-p22 unknown Template:OMIM2
DBA3 10q22-q23 Template:OMIM2 Template:OMIM2 RPS24[25] 30S to 18S[10]: 291 (cite)
DBA4 15q Template:OMIM2 Template:OMIM2 RPS17[26] 30S to 18S[10]: 291 
DBA5 3q29-qter Template:OMIM2 Template:OMIM2 RPL35A[27] 32S to 5.8S/28S[10]: 291 (cite)
DBA6 1p22.1 Template:OMIM2 Template:OMIM2 RPL5[28] 32S to 5.8S/28S[10]: 291 
DBA7 1p36.1-p35 Template:OMIM2 Template:OMIM2 RPL11[28] 32S to 5.8S/28S[10]: 291 
DBA8 2p25 Template:OMIM2 Template:OMIM2 RPS7[28] 30S to 18S[10]: 291 
DBA9 6p Template:OMIM2 Template:OMIM2 RPS10[24] 30S to 18S[29]
DBA10 12q Template:OMIM2 Template:OMIM2 RPS26 30S to 18S[30]
DBA11 17p13 Template:OMIM2 Template:OMIM2 RPS26 30S to 18S[30]
DBA12 3p24 Template:OMIM2 Template:OMIM2 RPL15 45S to 32S[31]
DBA13 14q Template:OMIM2 Template:OMIM2 RPS29
DKCX Xq28 Template:OMIM2 Template:OMIM2 dyskerin associated with both H/ACA small nucleolar RNA (snoRNA) and with the RNA component of TERC[32]
TCS
5q- 5q33.1 Template:OMIM2 Template:OMIM2 RPS14 30S to 18S[10]: 291 
SDS 7q11.21 Template:OMIM2 Template:OMIM2 SBDS 60S to 80S[10]: 291 
CHH 9p13.3 Template:OMIM2 Template:OMIM2 RMRP mitochondrial RNA processing
NAIC 16q22.1 Template:OMIM2 Template:OMIM2 cirhin partial loss of interaction between cirhin and NOL11[33]
ICAS 3p22.1 Template:OMIM2 Template:OMIM2 RPSA
BWCNS 12p13.31 Template:OMIM2 Template:OMIM2 EMG1 18S to 40S
CHARGE 8q12.1-q12.2; also 7q21.11 Template:OMIM2 Template:OMIM2 CHD7; also SEMA3E
ACES Template:OMIM2 Template:OMIM2 RBM28

Several ribosomopathies share features such as inherited bone marrow failure, which is characterized a reduced number of blood cells and by a predisposition to cancer.[5] Other features can include skeletal abnormalities and growth retardation.[15] However, clinically these diseases are distinct, and do not show a consistent set of features.[15]

Diamond–Blackfan anemia

With the exception of rare GATA1 genotypes,(cite) Diamond–Blackfan anemia (DBA) arises from a variety of mutations that cause ribosomopathies.[34]

Dyskeratosis congenita

The X-linked subtype of dyskeratosis congenita (DKCX)

Shwachman–Diamond syndrome

Shwachman–Diamond syndrome (SDS) is caused by bi-allelic mutations in the SBDS protein that affects its ability to couple GTP hydrolysis by the GTPase EFL1 to the release of eIF6 from the 60S subunit.[35] Clinically, SDS affects multiple systems, causing bony abnormalities, and pancreatic and neurocognitive dysfunction.[36] SBDS associates with the 60S subunit in human cells and has a role in subunit joining and translational activation in yeast models.

5q- myelodysplastic syndrome

5q- myelodysplastic syndrome (MDS)[36] is associated with acquired haplo-insufficiency of RPS14,[37] a component of the eukaryotic small ribosomal subunit (40S).[5] RPS14 is critical for 40S assembly, and depletion of RPS14 in human CD34(+) cells is sufficient to recapitulate the 5q- defect of erythropoiesis with sparing of megakaryocytes.[5]

Treacher Collins syndrome

Treacher Collins syndrome (TCS)

Cartilage–hair hypoplasia

Cartilage–hair hypoplasia (CHH) - some sources list confidently as ribosomopathy, others question[citation needed]

North American Indian childhood cirrhosis

Main article: North American Indian childhood cirrhosis

NAIC is an autosomal recessive abnormality of the CIRH1A gene, which codes for cirhin. Neonatal jaundice advances over time to biliary cirrhosis with severe liver fibrosis.

Isolated congenital asplenia

Main article: Isolated congenital asplenia

Bowen–Conradi syndrome

Main article: Bowen–Conradi syndrome

Bowen–Conradi syndrome (BCS[38] or BWCNS[39]) is an autosomal recessive abnormality of the EMG1 gene, which plays a role in small ribosomal subunit (SSU) assembly.[38][40][41] Most affected children have been from North American Hutterite families, but BWCNS can affect other population groups.[39][42] Skeletal dysmorphology is seen[39][42] and severe prenatal and postnatal growth failure usually leads to death by one year of age.[43]

Other

UTP14

implicated in infertility, ovarian cancer, and scleroderma[38][44]

Familial colorectal cancer type X

Unlike the mutations of the 5 genes associated with DNA mismatch repair, which are associated with Lynch syndrome with hereditary nonpolyposis colorectal cancer (HNPCC) due to microsatellite instability, familial colorectal cancer (CRC) type X (FCCX) gives rise to HNPCC despite microsatellite stability.[45] FCCX is most likely etiologically heterogeneous but RPS20 may be implicated in some cases.[45]

p53

The p53 pathway is central to the ribosomopathy phenotype.[46] Ribosomal stress triggers activation of the p53 signaling pathway.[47][48]

Cancer

Cancer cells have irregularly shaped, large nucleoli, which may correspond ribosomal gene transcription up-regulation, and hence high cell proliferation. Oncogenes, like c-Myc, can upregulate rDNA transcription in a direct and indirect fashion. Tumor suppressors like Rb and p53, on the other hand, can suppress ribosome biogenesis. Additionally, the nucleolus is an important cellular sensor for stress and plays a key role in the activation of p53.

Ribosomopathy has been linked to the pathology of various malignancies.[46] Several ribosomopathies are associated with an increased rate of cancer. For example, both SDS and 5q- syndrome lead to impaired hematopoiesis and a predisposition to leukemia.[36] Additionally, acquired defects in ribosomal proteins that have not been implicated in congenital ribosomopathies have been found in T-lymphoblastic leukemia/lymphoma, stomach cancer and ovarian cancer.[3]

New cancer therapies might therefore target ribosome biogenesis specifically. As of 2014, two experimental agents inhibit RNA polymerase I by disrupting the rDNA promotor complex: CX-5461 activates p53 via nuclear stress and induces apoptosis of leukemia and lymphoma cells while leaving normal cells unharmed; BMH-21, inhibits rDNA transcription and induces nucleolar capping or nucleolar reorganization. This nucleolar stress eventually causes decreased cell proliferation and death. It also activates p-53 but p-53 activation was not required for the drug to be effective. The promise of these drugs is that they leave healthy cell DNA unharmed and specifically target the fact that cancer cells rely heavily on ribosome biogenesis. It has been said that ribosome biogenesis is the “Achilles heel in cancer cells.” [49]

References

  1. ^ Nakhoul H, Ke J, Zhou X, et al. (2014). "Ribosomopathies: Mechanisms of disease". Clinical Medicine Insights: Blood Disorders. 7: 7–16. doi:10.4137/CMBD.S16952. PMC 4251057. PMID 25512719.
  2. ^ a b c Narla, A; Ebert, B. L. (2010). "Ribosomopathies: Human disorders of ribosome dysfunction". Blood 115 (16): 3196–205. doi:10.1182/blood-2009-10-178129. PMC 2858486. PMID 20194897
  3. ^ a b "Ribosomopathies and the paradox of cellular hypo- to hyperproliferation". Blood. 125 (9): 1377–82. 2015. doi:10.1182/blood-2014-10-569616. PMC 4342353. PMID 25575543. {{cite journal}}: Unknown parameter |authors= ignored (help)
  4. ^ Ban N, Beckmann R, Cate JH, et al. (2014). "A new system for naming ribosomal proteins". Curr. Opin. Struct. Biol. 24: 165–9. doi:10.1016/j.sbi.2014.01.002. PMC 4358319. PMID 24524803.
  5. ^ a b c d e "Marrow failure: a window into ribosome biology". Blood. 124 (18): 2784–92. 2014. doi:10.1182/blood-2014-04-526301. PMID 25237201. {{cite journal}}: Unknown parameter |authors= ignored (help)
  6. ^ "Homo sapiens 28S ribosomal RNA". National Center for Biotechnology Information.
  7. ^ "Homo sapiens 5.8S ribosomal RNA". National Center for Biotechnology Information.
  8. ^ "Homo sapiens 18S ribosomal RNA". National Center for Biotechnology Information.
  9. ^ "Homo sapiens 5S ribosomal RNA". National Center for Biotechnology Information.
  10. ^ a b c d e f g h i j Hoffbrand, AV; Moss PAH. (2011). Essential Haematology (6th ed.). Wiley-Blackwell. ISBN 978-1-4051-9890-5.
  11. ^ Online Mendelian Inheritance in Man. OMIM entry 305000: Dyskeratosis congenita, X–linked; DKCX. Johns Hopkins University. [1]
  12. ^ Stumpf C. R.; Ruggero D (2011). "The cancerous translation apparatus". Current Opinion in Genetics & Development. 21 (4): 474–83. doi:10.1016/j.gde.2011.03.007. PMC 3481834. PMID 21543223.
  13. ^ Dauwerse JG; Dixon J; Seland S; et al. (2011). "Mutations in genes encoding subunits of RNA polymerases I and III cause Treacher Collins syndrome". Nature Genetics. 43 (1): 20–2. doi:10.1038/ng.724. PMID 21131976. {{cite journal}}: Unknown parameter |name-list-format= ignored (|name-list-style= suggested) (help)
  14. ^ Narla A; Hurst S. N.; Ebert B. L. (2011). "Ribosome defects in disorders of erythropoiesis". International Journal of Hematology. 93 (2): 144–9. doi:10.1007/s12185-011-0776-0. PMC 3689295. PMID 21279816.
  15. ^ a b c d "Genetics. Mysterious ribosomopathies". Science. 341 (6148): 849–50. 2013. doi:10.1126/science.1244156. PMC 3893057. PMID 23970686. {{cite journal}}: Unknown parameter |authors= ignored (help)
  16. ^ Online Mendelian Inheritance in Man. OMIM entry 271400: Asplenia, isolated congenital; ICAS. Johns Hopkins University. [2]
  17. ^ Online Mendelian Inheritance in Man. OMIM entry 150370: Ribosomal protein SA; RPSA. Johns Hopkins University. [3]
  18. ^ Bolze A, Mahlaoui N, Byun M, et al. (2013). "Ribosomal protein SA haploinsufficiency in humans with isolated congenital asplenia". Science. 340 (6135): 976–8. doi:10.1126/science.1234864. PMC 3677541. PMID 23579497.
  19. ^ Wong, M. T.; Schölvinck, E. H.; Lambeck, A. J.; Van Ravenswaaij-Arts, C. M. (2015). "CHARGE syndrome: A review of the immunological aspects". European Journal of Human Genetics. 23: 1451–9. doi:10.1038/ejhg.2015.7. PMID 25689927.
  20. ^ Martin, D. M. (2015). "Epigenetic Developmental Disorders: CHARGE syndrome, a case study". Current Genetic Medicine Reports. 3 (1): 1–7. doi:10.1007/s40142-014-0059-1. PMC 4325366. PMID 25685640.
  21. ^ Hsu, P; Ma, A; Wilson, M; Williams, G; Curotta, J; Munns, C. F.; Mehr, S (2014). "CHARGE syndrome: A review". Journal of Paediatrics and Child Health. 50 (7): 504–11. doi:10.1111/jpc.12497. PMID 24548020.
  22. ^ Janssen, N; Bergman, J. E.; Swertz, M. A.; Tranebjaerg, L; Lodahl, M; Schoots, J; Hofstra, R. M.; Van Ravenswaaij-Arts, C. M.; Hoefsloot, L. H. (2012). "Mutation update on the CHD7 gene involved in CHARGE syndrome". Human Mutation. 33 (8): 1149–60. doi:10.1002/humu.22086. PMID 22461308.
  23. ^ Template:OMIM2
  24. ^ a b c Online Mendelian Inheritance in Man. OMIM entry 105650: Diamond-Blackfan anemia. Johns Hopkins University. [4]
  25. ^ Gazda HT, Grabowska A, Merida-Long LB, et al. (December 2006). "Ribosomal protein S24 gene is mutated in Diamond–Blackfan anemia". Am. J. Hum. Genet. 79 (6): 1110–8. doi:10.1086/510020. PMC 1698708. PMID 17186470.
  26. ^ Cmejla R, Cmejlova J, Handrkova H, Petrak J, Pospisilova D (December 2007). "Ribosomal protein S17 gene (RPS17) is mutated in Diamond–Blackfan anemia". Hum. Mutat. 28 (12): 1178–82. doi:10.1002/humu.20608. PMID 17647292.
  27. ^ Farrar JE, Nater M, Caywood E, et al. (September 2008). "Abnormalities of the large ribosomal subunit protein, Rpl35a, in Diamond–Blackfan anemia". Blood. 112 (5): 1582–92. doi:10.1182/blood-2008-02-140012. PMC 2518874. PMID 18535205.
  28. ^ a b c Gazda H. T.; Sheen M. R.; Vlachos A; et al. (2008). "Ribosomal protein L5 and L11 mutations are associated with cleft palate and abnormal thumbs in Diamond-Blackfan anemia patients". The American Journal of Human Genetics. 83 (6): 769–80. doi:10.1016/j.ajhg.2008.11.004. PMC 2668101. PMID 19061985.
  29. ^ Online Mendelian Inheritance in Man. OMIM entry 603632: Ribosomal protein S10; RPS10. Johns Hopkins University. [5]
  30. ^ a b Online Mendelian Inheritance in Man. OMIM entry 603701: Ribosomal protein S26; RPS26. Johns Hopkins University. [6]
  31. ^ Online Mendelian Inheritance in Man. OMIM entry 604174: Ribosomal protein L15; RPL15. Johns Hopkins University. [7]
  32. ^ Template:OMIM2
  33. ^ "NOL11, implicated in the pathogenesis of North American Indian childhood cirrhosis, is required for pre-rRNA transcription and processing". PLoS Genet. 8 (8): e1002892. 2012. doi:10.1371/journal.pgen.1002892. PMC 3420923. PMID 22916032. {{cite journal}}: Unknown parameter |authors= ignored (help)CS1 maint: unflagged free DOI (link)
  34. ^ Boria I; Garelli E; Gazda H. T.; et al. (2010). "The ribosomal basis of Diamond-Blackfan Anemia: Mutation and database update". Human Mutation. 31 (12): 1269–79. doi:10.1002/humu.21383. PMID 20960466.
  35. ^ Finch A. J.; Hilcenko C; Basse N; et al. (2011). "Uncoupling of GTP hydrolysis from eIF6 release on the ribosome causes Shwachman-Diamond syndrome". Genes & Development. 25 (9): 917–29. doi:10.1101/gad.623011. PMC 3084026. PMID 21536732.
  36. ^ a b c Burwick N; Shimamura A; Liu J. M. (2011). "Non-Diamond Blackfan anemia disorders of ribosome function: Shwachman Diamond syndrome and 5q- syndrome". Seminars in Hematology. 48 (2): 136–43. doi:10.1053/j.seminhematol.2011.01.002. PMC 3072806. PMID 21435510.
  37. ^ "Non-Diamond Blackfan anemia disorders of ribosome function: Shwachman Diamond syndrome and 5q- syndrome". Semin. Hematol. 48 (2): 136–43. 2011. doi:10.1053/j.seminhematol.2011.01.002. PMC 3072806. PMID 21435510. {{cite journal}}: Unknown parameter |authors= ignored (help)
  38. ^ a b c "Human diseases of the SSU processome". Biochim. Biophys. Acta. 1842 (6): 758–64. 2014. doi:10.1016/j.bbadis.2013.11.004. PMID 24240090. {{cite journal}}: Unknown parameter |authors= ignored (help)
  39. ^ a b c Online Mendelian Inheritance in Man. OMIM entry 211180: XXX. Johns Hopkins University. [8]
  40. ^ Online Mendelian Inheritance in Man. OMIM entry 611531: Essential for mitotic growth 1, S. cervevisiae, Homolog of; EMG1. Johns Hopkins University. [9]
  41. ^ "Mystery behind Bowen-Conradi syndrome solved: a novel ribosome biogenesis defect". Clin. Genet. 77 (2): 116–8. 2010. doi:10.1111/j.1399-0004.2009.01304.x. PMID 20096068. {{cite journal}}: Unknown parameter |authors= ignored (help)
  42. ^ a b "Mutation of a gene essential for ribosome biogenesis, EMG1, causes Bowen-Conradi syndrome". Am. J. Hum. Genet. 84 (6): 728–39. 2009. doi:10.1016/j.ajhg.2009.04.017. PMC 2694972. PMID 19463982. {{cite journal}}: Unknown parameter |authors= ignored (help)
  43. ^ Armistead J, Patel N, Wu X, et al. (2015). "Growth arrest in the ribosomopathy, Bowen-Conradi syndrome, is due to dramatically reduced cell proliferation and a defect in mitotic progression". Biochim. Biophys. Acta. 1852 (5): 1029–37. doi:10.1016/j.bbadis.2015.02.007. PMID 25708872.
  44. ^ "Does expression of the retrogene UTP14c in the ovary pre-dispose women to ovarian cancer?". Med. Hypotheses. 78 (4): 446–9. 2012. doi:10.1016/j.mehy.2011.12.016. PMID 22285623. {{cite journal}}: Unknown parameter |authors= ignored (help)
  45. ^ a b "Exome sequencing in familial colorectal cancer: searching for needles in haystacks". Gastroenterology. 147 (3): 554–6. 2014. doi:10.1053/j.gastro.2014.07.031. PMID 25075943. {{cite journal}}: Unknown parameter |authors= ignored (help)
  46. ^ a b Raiser D. M.; Narla A; Ebert B. L. (2014). "The emerging importance of ribosomal dysfunction in the pathogenesis of hematologic disorders". Leukemia & Lymphoma. 55 (3): 491–500. doi:10.3109/10428194.2013.812786. PMID 23863123.
  47. ^ "Ribosomal proteins: functions beyond the ribosome". J Mol Cell Biol. 7: 92–104. 2015. doi:10.1093/jmcb/mjv014. PMID 25735597. {{cite journal}}: Unknown parameter |authors= ignored (help)
  48. ^ "Ribosomal proteins and human diseases: pathogenesis, molecular mechanisms, and therapeutic implications". Med Res Rev. 35 (2): 225–85. 2015. doi:10.1002/med.21327. PMID 25164622. {{cite journal}}: Unknown parameter |authors= ignored (help)
  49. ^ van Sluis, Marjolein; McStay, Brian (May 2014). "Ribosome Biogenesis: Achilles heel of cancer?". Genes & Cancer. 5 (5–6): 152–153. PMC 4104764. PMID 25061498.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Ribosomopathy&oldid=722432502"